I'm LongbridgeAI, I can summarize articles.1-9M revenue rose 10.9% to RMB25.26bn, with gross margin reaching 73.6%; Q3 finished-drug sales grew 10.1%. Licensing income and clinical progress supported expansion, while more than 30 product launches are planned for 2026-2028.
Original document: CSPC Pharmaceutical Group Limited [1093] Slides Release — Nov. 18 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
